Dr. Reddy’s Laboratories Ltd., Galderma dermatology news

Dr. Reddy’s filed three inter partes review (IPR) petitions with the Patent Trials and Appeals Board (PTAB) of the U.S. Patent and Trademark Office challenging Galderma’s U.S. Patent No. 8,603,506. The methods of use patent covers Galderma’s rosacea drug Oracea doxycycline and expires in 2022. The patent is one of 11 Orange Book-listed patents covering the once-daily modified-release formulation of doxycycline; the last patent expires in 2027. Oracea uses drug delivery technology from Supernus Pharmaceuticals Inc. (NASDAQ:SUPN, Rockville, Md.), which receives royalties from Oracea sales. ...